GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering

Recent studies indicate that GLP-1 receptor agonists (GLP-1RAs), used for type 2 diabetes and weight loss, are associated with a lower incidence of obesity-related cancers compared to other diabetes drugs such as DPP-4 inhibitors and insulins245.

A large cohort study found that patients with type 2 diabetes using GLP-1RAs had a significant reduction in the risk of developing 10 out of 13 obesity-associated cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, meningioma, and multiple myeloma, compared to those treated with insulin4.

A separate assessment of over 170,000 patients showed a 7% lower incidence of obesity-related cancers and an 8% decrease in all-cause mortality among GLP-1RA users5.

Methodological challenges remain, but the evidence for cancer prevention with GLP-1RAs is growing and is a topic of ongoing research3.

Recent news also notes that shares of Gyre stock fell after disappointing hepatitis B trial data and a subsequent share offering, though details on this are limited in the current search results.

Sources:

2. https://www.cancernetwork.com/view/glp-1-use-not-linked-to-increased-obesity-related-cancer-rates

3. https://pubmed.ncbi.nlm.nih.gov/40361378/

4. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833

5. http://www.cancernetwork.com/view/glp-1-use-not-linked-to-increased-obesity-related-cancer-rates